This is the OzemPic competitor once a month. He just achieved great results

The need to take Ozmpic or other medications can be real pain in the rear, as users must often have to overcome themselves once every week. In newly released clinical trial data, Maritide Amgen experimental time was performed once a month in addition to or even better than the current GLP-1 and Terzopatid drugs.

People who take Maritide constantly weight more than those in the imaginary medicine, as some lost up to 20 % of their basic weight throughout the year. Amgen advances to the experiences of the third stage of Maritide, which paves the way for fierce competition between the next generation of obesity medications. AMGEN presented the full results of the trial of the second stage of Maritide this week at the annual American Diabetes Association meeting; The results were also Published In New England Medicine.

Such as semaglutide (Ozmpic and Wegovy) and Tirzepatide (Zepbound and Mountaro) before that, Maritide GLP-1 mimics, which is an important hormone to regulate our hunger and blood sugar. But injection drugs have some new tricks. In addition, the drug carries a molecule targeting GIP, another important hormone associated with hunger. Interestingly, Tirzepatide mimics GIP, but Maritide prevents it (this indicates that the role of GIP in controlling our weight is very complex). The experimental medicine also contains an anti -laboratory body to be preserved in our system for a long time, so it is intended to be taken monthly or once every two months, compared to the weekly shots needed for Simajlotide and Terzopatid.

The second stage experience included approximately 600 adults, some of them suffer from type 2 diabetes and others with obesity only. For those who are obese only, people have lost up to 20 % of their average weight over 52 weeks (the imaginary drug loss with an average of 2.6 % of body weight). People with type 2 diabetes have lost an average of 17 % of their weight. These results, although they are not comparable directly at this stage, are equal to the clinical experience data of the latest GLP-1. Since the participants were still continuing to get rid of a pound at the end of the study, it is possible that the typical weight loss seen with Maritide is higher.

“Maritide has achieved a strong effectiveness, including the constant weight loss without a plateau in studying the second stage of 52 weeks and significant improvements in heart risk factors, which represents a specific progress of the field of obesity,” said Jay Praader, the Executive Vice President of Research and Development at AMGEN. statement From the company.

Not everything with Maritide is sunlight and jar, however. Vomiting rates were much higher among certain groups of people in Maritide, for example, which mostly contributed to the high rate of people before the end of the study. But some data also indicates that this side effect can be reduced by gradually raising the doses of people over time, similar to how to manage the current GLP-1 medications.

Amgen will test this overlapping doses strategy in the third stage of Maritide for people with obesity and type 2 diabetes, which has already started joining. The company also plans to launch the third stage experiments of cardiovascular disease, stop sleeping during sleep and heart failure. But it is far from alone in the arms race to develop more effective or practical treatments. Dozens of other candidates in the pipeline, each of which has its potential advantages on today’s medicines, such as being available through birth control pills or coming without Intestinal side effects Common in GLP-1S.

Of course, not all of these experimental medications will not succeed, but it seems likely that Smaglutide and Tirzepatide soon will soon be the only options available to obese people.